MiMedx Group Inc. announced the launch of its newest tissue product, AmnioFix Injectable, at the American Academy of Orthopaedic Surgeons 2012 Annual Meeting in San Francisco.
According to a company press release, AmnioFix Injectable is an allograft composed of micronized amniotic tissue, which is processed to optimize surgical performance and ease of use. The company’s proprietary Purion process retains the amniotic growth factors and cytokines inherent in and unique to placental tissue, resulting in an injectable tissue that offers a natural ability to reduce inflammation at the injection site and enhance soft tissue healing. AmnioFix has a 5-year shelf-life.
